Propanc Biopharma (PPCB) Assets Average (2012 - 2025)
Propanc Biopharma (PPCB) posted quarterly Assets Average of $16.5 million for Q4 2025, up 23171.85% year-over-year from N/an in Q4 2024, and down 12.02% quarter-over-quarter from $18.8 million in Q3 2025.
Propanc Biopharma (PPCB) Assets Average (2012 - 2025) Analysis & Trends
Propanc Biopharma (PPCB) has reported Assets Average for 14 consecutive years, with $16.5 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Assets Average rose 23171.85% year-over-year to $16.5 million; the TTM figure through Dec 2025 stood at $16.5 million (up 23171.85% YoY), while the FY2025 annual figure was $9.9 million, up 14749.44% from the prior year.
- Assets Average eased to $16.5 million in Q4 2025 per PPCB's latest filing, from $18.8 million in the prior quarter.
- Across five years, Assets Average topped out at $21.1 million in Q2 2025 and bottomed at $20572.0 in Q2 2021.
- Historically, Assets Average has averaged $3.5 million across 5 years, with a median of $111192.2 in 2023.
- Annual changes were most pronounced in 2021 — Assets Average slumped 74.67% — and 2025, when it surged 38330.62%.
- Propanc Biopharma's Assets Average stood at $86171.0 in 2021, then climbed by 17.37% to $101138.0 in 2022, then soared by 108.76% to $211139.0 in 2023, then sank by 66.33% to $71088.5 in 2024, then jumped by 23171.85% to $16.5 million in 2025.
- Business Quant data shows PPCB's Assets Average at $16.5 million in Q4 2025, $18.8 million in Q3 2025, and $21.1 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Propanc Biopharma | 587,855.41 | 587,855.41 | - | 16.54 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 16.54 Mn |
| Sep 30, 2025 | 18.80 Mn |
| Jun 30, 2025 | 21.08 Mn |
| Mar 31, 2025 | 11.30 Mn |
| Dec 31, 2024 | 71,088.50 |
| Sep 30, 2024 | 68,004.50 |
| Jun 30, 2024 | 54,851.00 |
| Mar 31, 2024 | 139,622.00 |
| Dec 31, 2023 | 211,139.00 |
| Sep 30, 2023 | 120,349.50 |
| Jun 30, 2023 | 102,035.00 |
| Mar 31, 2023 | 125,882.00 |
| Dec 31, 2022 | 101,138.00 |
| Sep 30, 2022 | 87,952.50 |
| Jun 30, 2022 | 125,555.50 |
| Mar 31, 2022 | 139,818.50 |
| Dec 31, 2021 | 86,171.00 |
| Sep 30, 2021 | 37,633.00 |
| Jun 30, 2021 | 20,572.00 |
| Mar 31, 2021 | 34,329.50 |